Back to results
US 8,409,816 B2Granted
Diabetes-related biomarkers and methods of use thereof
AssigneeTethys Bioscience, Inc.
InventorsMichael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
Life of this patent
Estimating the term…
Abstract
The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
Claims38
A method for monitoring a treatment regimen to delay or prevent an individual's conversion to a frank Diabetes disease state, the method comprising:
- (a) obtaining from at least one biological sample isolated from said individual undergoing said treatment regimen measurements of biomarkers comprising the biomarkers ADIPOQ (Adiponectin), GLUCOSE and CRP (C-Reactive Protein), and further comprising at least one biomarker selected from the group consisting of HBA1C (Glycosylated Hemoglobin), IGFBP1 (Insulin-like growth factor binding protein 1), IGFBP2 (Insulin-like growth factor binding protein 2), Insulin, LEP (Leptin) and TRIG (Triglycerides);
- (b) calculating the individual's risk for developing a diabetic condition from the output of a model, wherein the inputs to said model comprise said measurements, and further wherein said model was developed by fitting data from a longitudinal study of a selected population of individuals and said fitted data comprises levels of said biomarkers and conversion to Diabetes in said selected population of individuals;
- and
- (c) comparing the calculated risk for said individual to a previously calculated risk obtained from at least one earlier sample from said individual.
1 more element
A method for monitoring a treatment regimen or to delay, or prevent an individual's conversion to a frank Diabetes disease state, the method comprising:
- (a) obtaining from at least one biological sample isolated from said individual undergoing said treatment regimen measurements of biomarkers comprising the biomarkers ADIPOQ (Adiponectin), GLUCOSE and CRP (C-Reactive Protein), and further comprising at least one biomarker selected from the group consisting of HBA1C (Glycosylated Hemoglobin), IGFBP1 (Insulin-like growth factor binding protein 1), IGFBP2 (Insulin-like growth factor binding protein 2), Insulin, LEP (Leptin) and TRIG (Triglycerides);
- (b) calculating the individual's risk for developing a diabetic condition from the output of a model, wherein the inputs to said model comprise said measurements, and further wherein said model was developed by fitting data from a longitudinal study of a selected population of individuals and said fitted data comprises levels of said biomarkers and conversion to Diabetes in said selected population of individuals;
- (c) storing said calculated risk on electronic data storage means
- (d) comparing the calculated risk for said individual to a previously calculated risk obtained from at least one earlier sample from said individual.
1 more element
A method for monitoring a treatment regimen to delay or prevent an individual's conversion to a frank Diabetes disease state, the method comprising:
- (a) obtaining from at least one biological sample isolated from said individual undergoing said treatment regimen measurements of biomarkers comprising the biomarkers ADIPOQ (Adiponectin), GLUCOSE and CRP (C-Reactive Protein), and further comprising at least one biomarker selected from the group consisting of HBA1C (Glycosylated Hemoglobin), IGFBP1 (Insulin-like growth factor binding protein 1), IGFBP2 (Insulin-like growth factor binding protein 2), Insulin, LEP (Leptin) and TRIG (Triglycerides);
- (b) calculating the individual's risk for developing a diabetic condition from the output of a model, wherein the inputs to said model comprise said measurements, and further wherein said model was developed by fitting data from a longitudinal study of a selected population of individuals and said fitted data comprises levels of said biomarkers and conversion to Diabetes in said selected population of individuals;
- (c) storing said calculated risk on electronic data storage means
- (d) comparing the calculated risk for said individual to a previously calculated risk obtained from at least one earlier sample from said individual and
- (f) advising said individual or a health care practitioner of whether there has been a change in calculated risk.
2 more elements
Dependencies are inferred from the claim text.